Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report. Taiho will pay $400 million upfront with up to $740 million in…
Otsuka's Taiho pays $400M to buy Swiss ADC partner. Taiho Pharmaceutical, a subsidiary of Otsuka Holdings, has agreed to acquire Swiss biotech Araris Biotech…
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech announced (April 28, 2026) that the FDA completed its IND review for ARC-02, enabling initiation of a…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Taiho (subsidiary of Otsuka) agreed to acquire Araris Biotech for $400M upfront and up to $740M in milestones. Deal brings AraLinQ proprietary ADC linker platform and three preclinical ADC products for hematological and solid tumors. Follows a 2023 research collaboration. Update (Apr 2026): the acquisition closed and the first AraLinQ-platform asset reached the clinic — Taiho Oncology advanced ARC-02, a CD79b-targeting MMAE ADC for non-Hodgkin lymphoma, into a Phase 1 dose-escalation trial following FDA IND clearance, the first human test of the AraLinQ platform.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Taiho Pharmaceutical Co., Ltd. / Araris Biotech AG (this deal) | 2025 | $1.1B | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2025 deals · Hematology deals